Click me

Invokana and Diabetic Ketoacidosis

INVOKANA & DIABETIC KETOACIDOSIS Invokana (canagliflozin) is a medication used to treat Type 2 diabetes. It is a member of the SGLT2 class of antidiabetic medication which also includes the medications empagloflozin (Jardiance) and dapagliflozin (Farxiga). In May 2015, the Food and Drug Administration (FDA) issued a warning statement regarding SGLT2 inhibitors, including Invokana and the increased risk of Diabetic Ketoacidosis (DKA) OVER |450,000 Invokana prescriptions are filled every three months in the U.S. Diabetic ketoacidosis, also called ketosis, occurs when the body begins to use fat stores as an energy source because sugar is unavailable to the cells. Ketones are a chemical substance which are a byproduct of fat metabolism and cause the blood to become acidic. Diabetic ketoacidosis can develop quickly and become life-threatening in a short period of time. Symptoms • Fatigue Increased thirst Shortness of breath GI disturbance (pain, nausea) Increased urination Weakness Invokana may also pose other side effect risks, some of which may be serious including: Impaired kidney function Hypotension particularly if patient had prior renal damage Caused by increased water loss in urine following sugar excretion Allergic or hypersensitivity Increased hemoglobin and potassium levels reactions Caused by decreased blood volume and diuretic effect Sy SEEGERWEISSur A DrugDangers W COMPLFX IITIGATI1ONISIMPLE IL STICE © 2015

Invokana and Diabetic Ketoacidosis

shared by drugdangers on Sep 30
The FDA issued a warning about Invokana and the increased risk of Diabetic Ketocidosis. This is an infographic outlining the side effects of Invokana.


drugs fda


Did you work on this visual? Claim credit!

Get a Quote

Embed Code

For hosted site:

Click the code to copy


Click the code to copy
Customize size